
Sign up to save your podcasts
Or


Kyle A. Hess, PharmD, BCPS Twitter: @KyleHessPharmD describes the pathophysiology of calcium channel blocker overdose, explains the rationale for use of insulin-euglycemic therapy in calcium channel blocker overdose and identifies differences between the pathophysiology of dihydropyridine overdose and non-dihydropyridine overdose.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
By Mayo Clinic4.6
4545 ratings
Kyle A. Hess, PharmD, BCPS Twitter: @KyleHessPharmD describes the pathophysiology of calcium channel blocker overdose, explains the rationale for use of insulin-euglycemic therapy in calcium channel blocker overdose and identifies differences between the pathophysiology of dihydropyridine overdose and non-dihydropyridine overdose.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.

78,312 Listeners

262 Listeners

290 Listeners

3,338 Listeners

56,404 Listeners

43 Listeners

401 Listeners

12 Listeners

18 Listeners

15 Listeners

9 Listeners

14,011 Listeners

14 Listeners

5 Listeners